Share Price and Basic Stock Data
Last Updated: November 17, 2025, 9:13 pm
| PEG Ratio | 1.18 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Indraprastha Medical Corporation Ltd operates within the Hospitals & Medical Services industry, showcasing a robust business model with a current market capitalization of ₹5,170 Cr. The company’s share price stood at ₹564, reflecting a price-to-earnings (P/E) ratio of 30.8, indicating a premium valuation in the healthcare sector. Revenue from operations has shown a consistent upward trajectory, rising from ₹888 Cr in FY 2022 to ₹1,099 Cr in FY 2023 and further to ₹1,245 Cr in FY 2024. The trailing twelve months (TTM) revenue reached ₹1,374 Cr. Quarterly sales figures illustrate a healthy growth pattern, with Q1 FY 2025 reporting ₹365 Cr, up from ₹307 Cr in Q1 FY 2024. This upward trend in revenue highlights the company’s successful strategy in expanding its healthcare services and enhancing operational efficiency, positioning it well in a competitive market.
Profitability and Efficiency Metrics
Indraprastha Medical Corporation has demonstrated strong profitability metrics, with a net profit of ₹168 Cr reported in the TTM. The operating profit margin (OPM) stood at 20%, reflecting effective cost management relative to industry standards. The company’s return on equity (ROE) was reported at an impressive 30.0%, while the return on capital employed (ROCE) reached 39.1%, both indicating efficient utilization of shareholders’ funds and capital. Over the fiscal years, net profit has steadily increased, from ₹59 Cr in FY 2022 to ₹161 Cr in FY 2025. Efficiency is further highlighted by a cash conversion cycle (CCC) of 20 days, significantly lower than the typical industry range, suggesting effective working capital management. The interest coverage ratio (ICR) of 42.57x indicates the company’s strong ability to meet its interest obligations, reinforcing its financial health.
Balance Sheet Strength and Financial Ratios
The balance sheet of Indraprastha Medical Corporation is characterized by a solid equity base, with reserves amounting to ₹505 Cr against borrowings of ₹33 Cr. This results in a low debt-to-equity ratio, underscoring the company’s conservative approach towards leveraging. The book value per share increased to ₹65.09 in FY 2025, reflecting the company’s growing asset base. Financial ratios reveal a current ratio of 2.41, indicating strong liquidity, while a quick ratio of 2.37 reinforces its ability to cover short-term liabilities without relying on inventory. The company’s price-to-book value (P/BV) ratio stood at 5.93x, suggesting that investors are willing to pay a premium for the stock compared to its net assets. Strong asset turnover of 1.72 signifies effective utilization of assets to generate revenue, further enhancing the company’s financial stability.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Indraprastha Medical Corporation reflects a stable ownership structure, with promoters holding 51% of the shares. This stability is complemented by a modest presence of foreign institutional investors (FIIs) at 2.41% and domestic institutional investors (DIIs) at 3.51%. The public holds 43.08% of the shares, indicating a broad base of retail investors. The number of shareholders has increased to 70,914, suggesting growing interest and confidence in the stock. The consistent promoter holding fosters investor trust, while the gradual increase in institutional ownership points to a positive perception of the company’s growth prospects. However, the relatively low FII and DII stakes may indicate caution among larger institutional players, which could be a point of consideration for potential investors.
Outlook, Risks, and Final Insight
Looking ahead, Indraprastha Medical Corporation is poised for continued growth, driven by its strong financial performance and operational efficiencies. However, the company faces risks such as potential regulatory changes in the healthcare sector and increasing competition, which could impact margins. Moreover, the reliance on domestic markets may expose the company to local economic fluctuations. Despite these risks, the company’s strong balance sheet and profitability metrics provide a solid foundation for future expansion. If Indraprastha Medical Corporation can navigate these challenges effectively, it may enhance its market position and shareholder value. Investors should closely monitor regulatory developments and competitive dynamics while considering the company’s historical performance as a basis for evaluation.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Indraprastha Medical Corporation Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 45.8 Cr. | 137 | 195/125 | 9.35 | 117 | 2.56 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 23.5 Cr. | 22.4 | 35.5/0.00 | 24.3 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 13.4 Cr. | 12.9 | 21.4/11.6 | 148 | 19.1 | 0.00 % | 3.00 % | 0.81 % | 10.0 |
| Fortis Malar Hospitals Ltd | 121 Cr. | 64.6 | 98.7/52.3 | 26.7 | 18.3 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 21.4 Cr. | 3.97 | 7.60/3.40 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 27,940.71 Cr | 851.94 | 103.13 | 98.97 | 0.31% | 15.48% | 14.81% | 9.04 |
All Competitor Stocks of Indraprastha Medical Corporation Ltd
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 263 | 284 | 277 | 274 | 307 | 317 | 306 | 315 | 348 | 350 | 325 | 334 | 365 |
| Expenses | 226 | 241 | 240 | 241 | 259 | 267 | 259 | 266 | 281 | 286 | 273 | 272 | 292 |
| Operating Profit | 37 | 44 | 37 | 33 | 47 | 50 | 47 | 48 | 67 | 64 | 52 | 61 | 73 |
| OPM % | 14% | 15% | 13% | 12% | 15% | 16% | 15% | 15% | 19% | 18% | 16% | 18% | 20% |
| Other Income | 1 | 1 | 3 | 5 | 4 | 4 | 4 | 5 | 5 | 6 | 5 | 6 | 7 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 2 |
| Depreciation | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 11 | 11 | 11 | 11 | 10 |
| Profit before tax | 27 | 34 | 29 | 27 | 40 | 44 | 41 | 42 | 60 | 57 | 45 | 55 | 68 |
| Tax % | 24% | 26% | 29% | 27% | 24% | 25% | 28% | 25% | 25% | 26% | 26% | 26% | 25% |
| Net Profit | 20 | 25 | 21 | 20 | 30 | 33 | 29 | 31 | 45 | 42 | 33 | 41 | 51 |
| EPS in Rs | 2.21 | 2.74 | 2.28 | 2.16 | 3.33 | 3.58 | 3.21 | 3.40 | 4.88 | 4.63 | 3.58 | 4.47 | 5.61 |
Last Updated: August 20, 2025, 9:05 am
Below is a detailed analysis of the quarterly data for Indraprastha Medical Corporation Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 365.00 Cr.. The value appears strong and on an upward trend. It has increased from 334.00 Cr. (Mar 2025) to 365.00 Cr., marking an increase of 31.00 Cr..
- For Expenses, as of Jun 2025, the value is 292.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 272.00 Cr. (Mar 2025) to 292.00 Cr., marking an increase of 20.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 73.00 Cr.. The value appears strong and on an upward trend. It has increased from 61.00 Cr. (Mar 2025) to 73.00 Cr., marking an increase of 12.00 Cr..
- For OPM %, as of Jun 2025, the value is 20.00%. The value appears strong and on an upward trend. It has increased from 18.00% (Mar 2025) to 20.00%, marking an increase of 2.00%.
- For Other Income, as of Jun 2025, the value is 7.00 Cr.. The value appears strong and on an upward trend. It has increased from 6.00 Cr. (Mar 2025) to 7.00 Cr., marking an increase of 1.00 Cr..
- For Interest, as of Jun 2025, the value is 2.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.00 Cr. (Mar 2025) to 2.00 Cr., marking an increase of 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 10.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 11.00 Cr. (Mar 2025) to 10.00 Cr., marking a decrease of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 68.00 Cr.. The value appears strong and on an upward trend. It has increased from 55.00 Cr. (Mar 2025) to 68.00 Cr., marking an increase of 13.00 Cr..
- For Tax %, as of Jun 2025, the value is 25.00%. The value appears to be improving (decreasing) as expected. It has decreased from 26.00% (Mar 2025) to 25.00%, marking a decrease of 1.00%.
- For Net Profit, as of Jun 2025, the value is 51.00 Cr.. The value appears strong and on an upward trend. It has increased from 41.00 Cr. (Mar 2025) to 51.00 Cr., marking an increase of 10.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 5.61. The value appears strong and on an upward trend. It has increased from 4.47 (Mar 2025) to 5.61, marking an increase of 1.14.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 5:09 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 678 | 714 | 755 | 766 | 753 | 788 | 831 | 613 | 888 | 1,099 | 1,245 | 1,356 | 1,405 |
| Expenses | 587 | 630 | 675 | 686 | 678 | 706 | 743 | 572 | 768 | 947 | 1,050 | 1,112 | 1,147 |
| Operating Profit | 91 | 85 | 80 | 79 | 74 | 82 | 87 | 41 | 120 | 152 | 195 | 245 | 258 |
| OPM % | 13% | 12% | 11% | 10% | 10% | 10% | 11% | 7% | 14% | 14% | 16% | 18% | 18% |
| Other Income | 1 | 1 | 1 | -0 | -1 | -1 | -0 | -0 | -3 | 9 | 16 | 22 | 26 |
| Interest | 10 | 8 | 7 | 8 | 9 | 7 | 6 | 3 | 3 | 4 | 4 | 6 | 6 |
| Depreciation | 28 | 28 | 35 | 31 | 31 | 30 | 33 | 33 | 35 | 39 | 40 | 44 | 43 |
| Profit before tax | 54 | 50 | 39 | 41 | 34 | 45 | 48 | 4 | 79 | 117 | 166 | 216 | 234 |
| Tax % | 35% | 34% | 37% | 36% | 38% | 36% | 9% | 46% | 26% | 26% | 25% | 26% | |
| Net Profit | 35 | 32 | 24 | 26 | 21 | 28 | 44 | 2 | 59 | 86 | 124 | 161 | 175 |
| EPS in Rs | 3.87 | 3.54 | 2.66 | 2.86 | 2.30 | 3.10 | 4.76 | 0.25 | 6.39 | 9.40 | 13.52 | 17.56 | 19.06 |
| Dividend Payout % | 47% | 51% | 68% | 63% | 65% | 52% | 0% | 0% | 39% | 32% | 33% | 26% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -8.57% | -25.00% | 8.33% | -19.23% | 33.33% | 57.14% | -95.45% | 2850.00% | 45.76% | 44.19% | 29.84% |
| Change in YoY Net Profit Growth (%) | 0.00% | -16.43% | 33.33% | -27.56% | 52.56% | 23.81% | -152.60% | 2945.45% | -2804.24% | -1.58% | -14.35% |
Indraprastha Medical Corporation Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 10% |
| 3 Years: | 15% |
| TTM: | 7% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 29% |
| 3 Years: | 37% |
| TTM: | 21% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 24% |
| 5 Years: | 58% |
| 3 Years: | 89% |
| 1 Year: | 8% |
| Return on Equity | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 23% |
| 3 Years: | 28% |
| Last Year: | 30% |
Last Updated: September 5, 2025, 7:30 am
Balance Sheet
Last Updated: November 9, 2025, 2:15 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 92 | 92 | 92 | 92 | 92 | 92 | 92 | 92 | 92 | 92 | 92 | 92 | 92 |
| Reserves | 95 | 103 | 132 | 139 | 141 | 152 | 176 | 181 | 234 | 288 | 386 | 505 | 567 |
| Borrowings | 63 | 50 | 52 | 67 | 66 | 21 | 4 | 3 | 5 | 2 | 34 | 33 | 31 |
| Other Liabilities | 199 | 196 | 185 | 160 | 134 | 157 | 177 | 157 | 131 | 173 | 212 | 222 | 264 |
| Total Liabilities | 449 | 442 | 460 | 458 | 432 | 422 | 449 | 432 | 462 | 555 | 723 | 852 | 954 |
| Fixed Assets | 293 | 286 | 301 | 296 | 294 | 280 | 303 | 283 | 277 | 275 | 347 | 328 | 351 |
| CWIP | 2 | 3 | 3 | 0 | 0 | 1 | 0 | 3 | 0 | 3 | 0 | 33 | 2 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 39 |
| Other Assets | 154 | 153 | 157 | 163 | 138 | 141 | 146 | 145 | 185 | 278 | 376 | 491 | 563 |
| Total Assets | 449 | 442 | 460 | 458 | 432 | 422 | 449 | 432 | 462 | 555 | 723 | 852 | 954 |
Below is a detailed analysis of the balance sheet data for Indraprastha Medical Corporation Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 92.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 92.00 Cr..
- For Reserves, as of Sep 2025, the value is 567.00 Cr.. The value appears strong and on an upward trend. It has increased from 505.00 Cr. (Mar 2025) to 567.00 Cr., marking an increase of 62.00 Cr..
- For Borrowings, as of Sep 2025, the value is 31.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 33.00 Cr. (Mar 2025) to 31.00 Cr., marking a decrease of 2.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 264.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 222.00 Cr. (Mar 2025) to 264.00 Cr., marking an increase of 42.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 954.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 852.00 Cr. (Mar 2025) to 954.00 Cr., marking an increase of 102.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 351.00 Cr.. The value appears strong and on an upward trend. It has increased from 328.00 Cr. (Mar 2025) to 351.00 Cr., marking an increase of 23.00 Cr..
- For CWIP, as of Sep 2025, the value is 2.00 Cr.. The value appears to be declining and may need further review. It has decreased from 33.00 Cr. (Mar 2025) to 2.00 Cr., marking a decrease of 31.00 Cr..
- For Investments, as of Sep 2025, the value is 39.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 39.00 Cr., marking an increase of 39.00 Cr..
- For Other Assets, as of Sep 2025, the value is 563.00 Cr.. The value appears strong and on an upward trend. It has increased from 491.00 Cr. (Mar 2025) to 563.00 Cr., marking an increase of 72.00 Cr..
- For Total Assets, as of Sep 2025, the value is 954.00 Cr.. The value appears strong and on an upward trend. It has increased from 852.00 Cr. (Mar 2025) to 954.00 Cr., marking an increase of 102.00 Cr..
Notably, the Reserves (567.00 Cr.) exceed the Borrowings (31.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 28.00 | 35.00 | 28.00 | 12.00 | 8.00 | 61.00 | 83.00 | 38.00 | 115.00 | 150.00 | 161.00 | 212.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 35 | 40 | 41 | 47 | 41 | 35 | 35 | 40 | 18 | 23 | 17 | 20 |
| Inventory Days | ||||||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 35 | 40 | 41 | 47 | 41 | 35 | 35 | 40 | 18 | 23 | 17 | 20 |
| Working Capital Days | -27 | -35 | -22 | -17 | -7 | -5 | -10 | -1 | -2 | -12 | -24 | -19 |
| ROCE % | 26% | 23% | 18% | 17% | 15% | 19% | 21% | 3% | 29% | 34% | 38% | 39% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Motilal Oswal S&P BSE Healthcare ETF | 384 | 0.08 | 0.01 | 384 | 2025-04-22 17:25:31 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 17.56 | 13.52 | 9.40 | 6.39 | 0.25 |
| Diluted EPS (Rs.) | 17.56 | 13.52 | 9.40 | 6.39 | 0.25 |
| Cash EPS (Rs.) | 22.40 | 17.89 | 13.68 | 10.21 | 3.89 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 65.09 | 52.12 | 41.39 | 35.50 | 29.75 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 65.09 | 52.12 | 41.39 | 35.50 | 29.75 |
| Dividend / Share (Rs.) | 4.50 | 4.50 | 3.00 | 2.50 | 0.00 |
| Revenue From Operations / Share (Rs.) | 147.96 | 135.78 | 119.85 | 96.89 | 66.91 |
| PBDIT / Share (Rs.) | 29.12 | 22.93 | 17.53 | 12.81 | 4.47 |
| PBIT / Share (Rs.) | 24.28 | 18.56 | 13.25 | 9.00 | 0.83 |
| PBT / Share (Rs.) | 23.60 | 18.12 | 12.78 | 8.63 | 0.46 |
| Net Profit / Share (Rs.) | 17.56 | 13.52 | 9.40 | 6.39 | 0.25 |
| PBDIT Margin (%) | 19.67 | 16.89 | 14.62 | 13.22 | 6.67 |
| PBIT Margin (%) | 16.41 | 13.67 | 11.05 | 9.28 | 1.24 |
| PBT Margin (%) | 15.94 | 13.34 | 10.66 | 8.90 | 0.69 |
| Net Profit Margin (%) | 11.86 | 9.95 | 7.84 | 6.60 | 0.37 |
| Return on Networth / Equity (%) | 26.98 | 25.94 | 22.70 | 18.01 | 0.85 |
| Return on Capital Employeed (%) | 33.07 | 30.50 | 28.54 | 22.40 | 2.41 |
| Return On Assets (%) | 18.90 | 17.13 | 15.51 | 12.69 | 0.53 |
| Asset Turnover Ratio (%) | 1.72 | 1.95 | 2.16 | 1.99 | 1.39 |
| Current Ratio (X) | 2.41 | 1.86 | 1.72 | 1.68 | 1.22 |
| Quick Ratio (X) | 2.37 | 1.82 | 1.66 | 1.58 | 1.14 |
| Inventory Turnover Ratio (X) | 186.83 | 0.00 | 21.00 | 18.55 | 10.95 |
| Dividend Payout Ratio (NP) (%) | 25.62 | 22.18 | 26.60 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 20.09 | 16.76 | 18.27 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | 74.38 | 77.82 | 73.40 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | 79.91 | 83.24 | 81.73 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 42.57 | 51.79 | 37.55 | 34.43 | 12.27 |
| Interest Coverage Ratio (Post Tax) (X) | 26.68 | 31.53 | 21.13 | 18.19 | 1.70 |
| Enterprise Value (Cr.) | 3217.17 | 1350.00 | 583.80 | 467.36 | 465.22 |
| EV / Net Operating Revenue (X) | 2.37 | 1.08 | 0.53 | 0.52 | 0.75 |
| EV / EBITDA (X) | 12.05 | 6.42 | 3.63 | 3.98 | 11.36 |
| MarketCap / Net Operating Revenue (X) | 2.61 | 1.26 | 0.64 | 0.60 | 0.80 |
| Retention Ratios (%) | 74.37 | 77.81 | 73.39 | 0.00 | 0.00 |
| Price / BV (X) | 5.93 | 3.30 | 1.88 | 1.65 | 1.81 |
| Price / Net Operating Revenue (X) | 2.61 | 1.26 | 0.64 | 0.60 | 0.80 |
| EarningsYield | 0.04 | 0.07 | 0.12 | 0.10 | 0.00 |
After reviewing the key financial ratios for Indraprastha Medical Corporation Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 17.56. This value is within the healthy range. It has increased from 13.52 (Mar 24) to 17.56, marking an increase of 4.04.
- For Diluted EPS (Rs.), as of Mar 25, the value is 17.56. This value is within the healthy range. It has increased from 13.52 (Mar 24) to 17.56, marking an increase of 4.04.
- For Cash EPS (Rs.), as of Mar 25, the value is 22.40. This value is within the healthy range. It has increased from 17.89 (Mar 24) to 22.40, marking an increase of 4.51.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 65.09. It has increased from 52.12 (Mar 24) to 65.09, marking an increase of 12.97.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 65.09. It has increased from 52.12 (Mar 24) to 65.09, marking an increase of 12.97.
- For Dividend / Share (Rs.), as of Mar 25, the value is 4.50. This value exceeds the healthy maximum of 3. There is no change compared to the previous period (Mar 24) which recorded 4.50.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 147.96. It has increased from 135.78 (Mar 24) to 147.96, marking an increase of 12.18.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 29.12. This value is within the healthy range. It has increased from 22.93 (Mar 24) to 29.12, marking an increase of 6.19.
- For PBIT / Share (Rs.), as of Mar 25, the value is 24.28. This value is within the healthy range. It has increased from 18.56 (Mar 24) to 24.28, marking an increase of 5.72.
- For PBT / Share (Rs.), as of Mar 25, the value is 23.60. This value is within the healthy range. It has increased from 18.12 (Mar 24) to 23.60, marking an increase of 5.48.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 17.56. This value is within the healthy range. It has increased from 13.52 (Mar 24) to 17.56, marking an increase of 4.04.
- For PBDIT Margin (%), as of Mar 25, the value is 19.67. This value is within the healthy range. It has increased from 16.89 (Mar 24) to 19.67, marking an increase of 2.78.
- For PBIT Margin (%), as of Mar 25, the value is 16.41. This value is within the healthy range. It has increased from 13.67 (Mar 24) to 16.41, marking an increase of 2.74.
- For PBT Margin (%), as of Mar 25, the value is 15.94. This value is within the healthy range. It has increased from 13.34 (Mar 24) to 15.94, marking an increase of 2.60.
- For Net Profit Margin (%), as of Mar 25, the value is 11.86. This value exceeds the healthy maximum of 10. It has increased from 9.95 (Mar 24) to 11.86, marking an increase of 1.91.
- For Return on Networth / Equity (%), as of Mar 25, the value is 26.98. This value is within the healthy range. It has increased from 25.94 (Mar 24) to 26.98, marking an increase of 1.04.
- For Return on Capital Employeed (%), as of Mar 25, the value is 33.07. This value is within the healthy range. It has increased from 30.50 (Mar 24) to 33.07, marking an increase of 2.57.
- For Return On Assets (%), as of Mar 25, the value is 18.90. This value is within the healthy range. It has increased from 17.13 (Mar 24) to 18.90, marking an increase of 1.77.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.72. It has decreased from 1.95 (Mar 24) to 1.72, marking a decrease of 0.23.
- For Current Ratio (X), as of Mar 25, the value is 2.41. This value is within the healthy range. It has increased from 1.86 (Mar 24) to 2.41, marking an increase of 0.55.
- For Quick Ratio (X), as of Mar 25, the value is 2.37. This value exceeds the healthy maximum of 2. It has increased from 1.82 (Mar 24) to 2.37, marking an increase of 0.55.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 186.83. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 186.83, marking an increase of 186.83.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 25.62. This value is within the healthy range. It has increased from 22.18 (Mar 24) to 25.62, marking an increase of 3.44.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 20.09. This value is within the healthy range. It has increased from 16.76 (Mar 24) to 20.09, marking an increase of 3.33.
- For Earning Retention Ratio (%), as of Mar 25, the value is 74.38. This value exceeds the healthy maximum of 70. It has decreased from 77.82 (Mar 24) to 74.38, marking a decrease of 3.44.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 79.91. This value exceeds the healthy maximum of 70. It has decreased from 83.24 (Mar 24) to 79.91, marking a decrease of 3.33.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 42.57. This value is within the healthy range. It has decreased from 51.79 (Mar 24) to 42.57, marking a decrease of 9.22.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 26.68. This value is within the healthy range. It has decreased from 31.53 (Mar 24) to 26.68, marking a decrease of 4.85.
- For Enterprise Value (Cr.), as of Mar 25, the value is 3,217.17. It has increased from 1,350.00 (Mar 24) to 3,217.17, marking an increase of 1,867.17.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.37. This value is within the healthy range. It has increased from 1.08 (Mar 24) to 2.37, marking an increase of 1.29.
- For EV / EBITDA (X), as of Mar 25, the value is 12.05. This value is within the healthy range. It has increased from 6.42 (Mar 24) to 12.05, marking an increase of 5.63.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.61. This value is within the healthy range. It has increased from 1.26 (Mar 24) to 2.61, marking an increase of 1.35.
- For Retention Ratios (%), as of Mar 25, the value is 74.37. This value exceeds the healthy maximum of 70. It has decreased from 77.81 (Mar 24) to 74.37, marking a decrease of 3.44.
- For Price / BV (X), as of Mar 25, the value is 5.93. This value exceeds the healthy maximum of 3. It has increased from 3.30 (Mar 24) to 5.93, marking an increase of 2.63.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.61. This value is within the healthy range. It has increased from 1.26 (Mar 24) to 2.61, marking an increase of 1.35.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has decreased from 0.07 (Mar 24) to 0.04, marking a decrease of 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Indraprastha Medical Corporation Ltd:
- Net Profit Margin: 11.86%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 33.07% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 26.98% (Industry Average ROE: 14.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 26.68
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.37
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 28.8 (Industry average Stock P/E: 103.13)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 11.86%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | Sarita Vihar, New Delhi Delhi 110076 | imclshares@apollohospitals.com http://www.apollohospitals.com |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Prathap C Reddy | Vice Chairman |
| Mr. Shivakumar Pattabhiraman | Managing Director |
| Mr. Sudhir Jalan | Director |
| Prof. (Dr) Mahesh Verma | Director |
| Mr. Salil Singhal | Director |
| Dr.(Ms.) Suneeta Reddy | Director |
| Mr. Vinayak Chatterjee | Director |
| Ms. Vineeta Rai | Director |
| Mr. Sandip Somany | Director |
| Mr. Tejpreet Singh Chopra | Director |
| Ms. Madhumita Ganguli | Director |
| Dr.(Ms.) Sangita Reddy | Director |
FAQ
What is the intrinsic value of Indraprastha Medical Corporation Ltd?
Indraprastha Medical Corporation Ltd's intrinsic value (as of 18 November 2025) is 500.35 which is 8.70% lower the current market price of 548.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 5,023 Cr. market cap, FY2025-2026 high/low of 641/307, reserves of ₹567 Cr, and liabilities of 954 Cr.
What is the Market Cap of Indraprastha Medical Corporation Ltd?
The Market Cap of Indraprastha Medical Corporation Ltd is 5,023 Cr..
What is the current Stock Price of Indraprastha Medical Corporation Ltd as on 18 November 2025?
The current stock price of Indraprastha Medical Corporation Ltd as on 18 November 2025 is 548.
What is the High / Low of Indraprastha Medical Corporation Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Indraprastha Medical Corporation Ltd stocks is 641/307.
What is the Stock P/E of Indraprastha Medical Corporation Ltd?
The Stock P/E of Indraprastha Medical Corporation Ltd is 28.8.
What is the Book Value of Indraprastha Medical Corporation Ltd?
The Book Value of Indraprastha Medical Corporation Ltd is 71.8.
What is the Dividend Yield of Indraprastha Medical Corporation Ltd?
The Dividend Yield of Indraprastha Medical Corporation Ltd is 0.82 %.
What is the ROCE of Indraprastha Medical Corporation Ltd?
The ROCE of Indraprastha Medical Corporation Ltd is 39.1 %.
What is the ROE of Indraprastha Medical Corporation Ltd?
The ROE of Indraprastha Medical Corporation Ltd is 30.0 %.
What is the Face Value of Indraprastha Medical Corporation Ltd?
The Face Value of Indraprastha Medical Corporation Ltd is 10.0.